Results 41 to 50 of about 50,819 (268)

Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes

Open Medicine, 2017
Therapeutic options for thymoma-associated myasthenia gravis (MG) patients complicated with hypertension and/or diabetes post thymectomy are often conventional steroids. As the prevalence of diabetes and hypertension globally increases, other therapeutic
Qi Guoyan, Xue Yinping, Li Yongzhao, Yang Hongxia, Zhang Xiaojing   +4 more
doaj   +1 more source

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset [PDF]

, 2020
[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).[Methods] This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular ...
Sevilla, Teresa, Gallardo, Eduard, García-Sobrino, Tania, Martín, María Asunción, Cortés-Vicente, Elena, Ramos-Fransi, Alba, Jericó, Ivonne, Albertí, María Antonia, Pelayo-Negro, Ana L., Segovia, Sonia, Casasnovas, Carlos, López de Munain, Adolfo, Fernández-Torrón, Roberto, Galán, Lucía, Rojas-García, Ricard, Lozano-Veintimilla, Ana, Galan, Luciía, Lopez-de-Munain, Adolfo, Illa, Isabel, Mendoza, María Dolores, Cano-Abascal, Ángel, Gutiérrez-Gutiérrez, Gerardo, Guerrero-Sola, Antonio, Pelayo-Negro, Ana Lara, Vélez Gómez, Beatriz, Paradas, Carmen, Velez, Beatriz, Gómez, María Teresa, Díaz-Manera, Jordi, Pardo, Julio, Álvarez-Velasco, Rodrigo, Martínez-Piñeiro, Alicia, Moris, Germán, Querol, Luis   +33 more
core   +1 more source

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source

Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study

Neurology and Therapy
Introduction High-dose intravenous methylprednisolone (IVMP) is effective in treating generalized myasthenia gravis (gMG), but early-stage transient aggravation and MG crisis can occur.
Shanshan Gu, Yongzhao Li, Huimin Dong, Hongxia Yang, Mei Ma, Mengna Li, Congya Yan, Pei Jia, Yaxuan Wang, Guoyan Qi   +9 more
doaj   +1 more source

Causal relationship between gut microbiota and myasthenia gravis: a bidirectional mendelian randomization study

Cell & Bioscience, 2023
Background Observational studies have demonstrated an association between gut microbiota and myasthenia gravis; however, the causal relationship between the two still lacks clarity.
Tengfei Su, Xiang Yin, Jiaxin Ren, Yue Lang, Weiguanliu Zhang, Li Cui   +5 more
doaj   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis [PDF]

, 2023
According to the principle, thymomas combined with myasthenia gravis (MG) require surgical treatment. However, patients with non-MG thymoma rarely develop MG and early- or late-onset MG after surgery is called postoperative MG (PMG).
Gao, Xinliang, Ma, Jianzun, Zhang, Wenyu, Li, Zhiqin, Liu, Wei, Bi, Taiyu, Tang, Mingbo, Wei, Shixiong, Dong, Junxue, Shao, Yifeng, Hong, Yang, Yin, Yipeng   +11 more
core   +1 more source

Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral dystrophy type 1 (FSHD1) shows clinical heterogeneity that is only partly explained by D4Z4 repeat unit (RU) size. Although immune and inflammatory mechanisms may contribute to disease variability, the prevalence and clinical impact of autoimmune diseases in FSHD remain unclear.
Jonathan Pini, Giulia Tammam, Andra Ezaru, Manuela Gambella, Benoît Sanson, Luisa Villa, Michele Cavalli, Mihai‐Bogdan Ioncea, Angela Puma, Sabrina Sacconi   +9 more
wiley   +1 more source

Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics

Frontiers in Immunology
BackgroundThymoma is often associated with myasthenia gravis (MG), and the resection of thymoma improves myasthenic symptoms in patients with thymoma and MG (TMG), but some patients still have no relief.
Xiaoting Lin, Xiaoting Lin, Xiaoting Lin, Xiaoting Lin, Peng Liu, Peng Liu, Peng Liu, Peng Liu, Guoyan Qi, Guoyan Qi, Guoyan Qi, Guoyan Qi   +11 more
doaj   +1 more source

Thymoma with Myasthenia Gravis in Adolescent [PDF]

, 2011
Thymomas are exceedingly rare in the first 20 years of life, Thymic lesions comprise approximately 2–3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
Shetty, Prasad K, Prasanna K Shetty,, Balaiah, K, Balaiah K,, Nayak, Ganesh, Shetty, Prasanna K, Ganesh Nayak,, Prasad K Shetty,   +7 more
core